Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $166,204.18 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 3,394 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $48.97, for a total transaction of $166,204.18. Following the sale, the insider now owns 5,796 shares in the company, valued at $283,830.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

William Guyer also recently made the following trade(s):

• On Friday, November 1st, William Guyer sold 6,606 shares of Corcept Therapeutics stock. The shares were sold at an average price of $48.97, for a total value of $323,495.82.
• On Tuesday, September 3rd, William Guyer sold 10,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.30, for a total value of $353,000.00.

Corcept Therapeutics Trading Up 4.2 %

Shares of CORT opened at $52.14 on Wednesday. The firm has a market capitalization of $5.46 billion, a price-to-earnings ratio of 41.38 and a beta of 0.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $52.35. The company has a 50-day moving average of $43.05 and a 200 day moving average of $35.12.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.14. The company had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. Corcept Therapeutics’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 earnings per share. On average, research analysts expect that Corcept Therapeutics Incorporated will post 1.25 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CORT. Canaccord Genuity Group restated a “buy” rating and issued a $38.00 price target on shares of Corcept Therapeutics in a research report on Tuesday, July 30th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a report on Thursday, October 31st. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Piper Sandler raised their price objective on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 18th. Finally, StockNews.com raised Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 31st. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $65.25.

Hedge Funds Weigh In On Corcept Therapeutics

Institutional investors have recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new stake in Corcept Therapeutics in the third quarter worth about $25,000. Park Place Capital Corp bought a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at about $32,000. Atwood & Palmer Inc. purchased a new stake in shares of Corcept Therapeutics in the 2nd quarter worth approximately $35,000. Kathleen S. Wright Associates Inc. bought a new position in shares of Corcept Therapeutics during the third quarter valued at approximately $36,000. Finally, Blue Trust Inc. boosted its stake in shares of Corcept Therapeutics by 125.4% during the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,962 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.